- Home
- CR vs RDY Comparison
CR vs RDY Comparison
Compare CR & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CR
- RDY
- Stock Information
- Founded
- CR 1855
- RDY 1984
- Country
- CR United States
- RDY India
- Employees
- CR N/A
- RDY N/A
- Industry
- CR Metal Fabrications
- RDY Biotechnology: Pharmaceutical Preparations
- Sector
- CR Industrials
- RDY Health Care
- Exchange
- CR Nasdaq
- RDY Nasdaq
- Market Cap
- CR 11.1B
- RDY 11.8B
- IPO Year
- CR N/A
- RDY N/A
- Fundamental
- Price
- CR $182.75
- RDY $14.73
- Analyst Decision
- CR Strong Buy
- RDY Strong Buy
- Analyst Count
- CR 5
- RDY 2
- Target Price
- CR $222.20
- RDY $16.95
- AVG Volume (30 Days)
- CR 321.8K
- RDY 797.2K
- Earning Date
- CR 10-27-2025
- RDY 11-04-2025
- Dividend Yield
- CR 0.50%
- RDY 0.49%
- EPS Growth
- CR 44.57
- RDY 2.20
- EPS
- CR 6.02
- RDY 0.79
- Revenue
- CR $2,227,200,000.00
- RDY $3,897,394,052.00
- Revenue This Year
- CR $10.55
- RDY $7.33
- Revenue Next Year
- CR $10.78
- RDY $1.96
- P/E Ratio
- CR $30.40
- RDY $18.69
- Revenue Growth
- CR 18.63
- RDY 15.86
- 52 Week Low
- CR $127.04
- RDY $12.26
- 52 Week High
- CR $203.89
- RDY $16.19
- Technical
- Relative Strength Index (RSI)
- CR 41.40
- RDY 61.58
- Support Level
- CR $180.51
- RDY $14.60
- Resistance Level
- CR $186.79
- RDY $14.85
- Average True Range (ATR)
- CR 4.13
- RDY 0.15
- MACD
- CR -0.44
- RDY 0.06
- Stochastic Oscillator
- CR 18.07
- RDY 84.62
About CR Crane Company
Crane is a diversified industrial firm that manufactures a broad range of products, including valves, pumps, aerospace components, and fiberglass-reinforced plastic panels. Its business is organized into two segments: aerospace and electronics, and process flow technologies. Crane generated approximately $2.1 billion in revenue in 2024.
About RDY Dr. Reddy's Laboratories Ltd
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.